Treatment of macular edema in diabetic retinopathy: Comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections

Expert Review of Ophthalmology

Volumn 9, Issue 2, 2014, Pages 139-143

  Ekinci, Metin ^a   Ceylan, Erdinç ^b   Çakici, Özgür ^c   Tanyildiz, Burak ^d   Olcaysu, Okan ^b   Çaǧatay, Halil Hüseyin ^a  

^a KAFKAS UNIVERSITY   (Turkey)

^b Erzurum Training and Research Hospital   (Turkey)

^c MUGLA SITKI KOCMAN UNIVERSITY   (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Bevacizumab; Diabetus mellitus; Macular edema; Optical coherence tomography; Ranibizumab

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFICACY; FEMALE; FOLLOW UP; FOVEAL THICKNESS; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RETINA FOVEA; RETINAL THICKNESS; VISUAL ACUITY;

EID: 84896901610     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.2014.900439     Document Type: Article

References (32)

1. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999;14:223-32
2. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, IV: Diabetic macular edama. Ophthalmology 1984;91:1464-74
3. Klein R, Moss SE, Klein BE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XI: The incidence of macular edema. Ophthalmology 1989;96:1501-2
4. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-2
5. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 2008;30: 65-84
6. Funatsu H, Noma H, Mimura T, et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009;116:73-9
7. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-90
8. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-8
9. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005
10. Bresnick GH. Diabetic maculopathy: A critical review highlighting diffuse macular edema. Ophthalmology 1983;90:1301-7
11. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest ophthalmol Vis Sci 2003;44:2155-62
12. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114: 1860-7
13. Ahmadieh H, Ramezani A, Shoeibi N, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: A placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008;246:483-9
14. The diabetes control and complications trial research group: The effect of intensive treatment of diabetes on the development and progression of long-Term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
15. Early Treatment Diabetic Retinopathy Study Research group. Photocoagulation for diabetic macular edama: Early Treatment Diabetic Retinopaty Study report number 1. Arch Ophthalmol 1995;113(9):1144-55
16. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema: Long term visual results. Ophthalmology 1991;98:1594-602
17. Harbour JM, Smiddy WE Jr, Rubsamen PE. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol 1996;121:405-13
18. Pendergast SD, Hassan TS, Williams GA, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophtalmol 2000;130:178-86
19. Jonas JB, Söfker A. Intraocular injection of cristalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001;132:425-7
20. Schalts H, Madeira D, Mc Donald R, Johnson RN. Progressive enlargement of laser scars following grid lazer photocoagulation for diffuse diabetic macular edema. Arch Ophtalmol 1991;109: 1549-51
21. Guyer DR, D'Amico DJ, Smith CW. Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am J Ophthalmol 1992;113:652-6
22. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of bloodretinal and blood-Aqueous barrier breakdown. Exp Eye Res 2005;80:249-58
23. Karaçorlu M, Ozdemir H, Senturk F, et al. Macular function after intravitreal triamcinolone acetonide injection for diabetic macular oedema. Acta Ophthalmol 2010;88(5):558-63
24. Ornek K, Ornek N. Intravitreal bevacizumab treatment for refractory diabetic macular edema. J Ocul Pharmacol Ther 2008;24(4):403-7
25. Astam N, Batioǧlu F, Ozmert E. Short-Term efficacy of intravitreal bevacizumab for the treatment of macular edema due to diabetic retinopathy and retinal vein occlusion. Int Ophthalmology 2009;29(5):343-8
26. Kook D, Wolf A, Kreutzer T, et al. Long-Term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008;28(8): 1053-60
27. Nguyen QD, Shah SM, Khwaja AA, et al. READ-2 study group. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2010;117(11):2146-51
28. Nepomuceno AB, Takaki E, Paes De Almeida FP, et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol 2013;156(3):502-10
29. Ford JA, Elders A, Shyangdan D, et al. The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: An indirect comparison in a systematic review. BMJ 2012;345:5182
30. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27(5): 536-44
31. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114(5):5-859
32. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007;27(9):1260-6.